Analyst consensus rating
Elicio Therapeutics Analyst Rating: none
Direct answer
Elicio Therapeutics's consensus rating is none.
3 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $13.67.
Forecast evidence checked October 17, 2026.
Get free Elicio Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.56
- Average price target
- $13.67
- High price target
- $23.00
- Low price target
- $8.00
- Low target gap
- +412.8%
- Target upside
- +776.1%
- High target gap
- +1,374.4%
- Target range width
- 961.5%
- Consensus rating
- none
- Analysts
- 3
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Elicio Therapeutics?
Elicio Therapeutics has a verified none consensus. The same dataset has an average price target of $13.67.
How far are Elicio Therapeutics's low and high targets from the recorded price?
The low target implies +412.8%, while the high target implies +1,374.4%.
How many analysts are included in Elicio Therapeutics's consensus?
The verified consensus includes 3 analysts.
How is Elicio Therapeutics's target upside or downside calculated?
The average target of $13.67 is divided by the recorded price of $1.56, then one is subtracted to produce +776.1%. This does not guarantee a future return.
When was Elicio Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.